Reasons for discontinuing oral anticoagulation therapy for atrial fibrillation: a systematic review
Age and Ageing2021Vol. 50(4), pp. 1108–1117
Citations Over TimeTop 10% of 2021 papers
Jackie Buck, Julia Hill, Alison Martin, Cassandra Springate, Bikramaditya Ghosh, Rachel Ashton, Geraldine Lee, Andi Orlowski
Abstract
The available evidence is derived from heterogeneous studies with few relevant data for the newer direct oral anticoagulants. Reasons underpinning decision-making to discontinue OAC from the perspective of patients, family carers and clinicians is poorly understood.
Related Papers
- → The role of factor Xa inhibitors in venous thromboembolism treatment(2015)48 cited
- → Expanding use of new oral anticoagulants(2014)17 cited
- → Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery(2015)5 cited
- → Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Non-Valvular Atrial Fibrillation(2016)4 cited
- → Novel Anticoagulants vs Warfarin for Stroke Prevention in Atrial Fibrillation(2014)1 cited